A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety and Tolerability of Lebrikizumab in Adolescent Patients With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication

Trial Profile

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety and Tolerability of Lebrikizumab in Adolescent Patients With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication

Completed
Phase of Trial: Phase III

Latest Information Update: 22 May 2017

At a glance

  • Drugs Lebrikizumab (Primary)
  • Indications Asthma
  • Focus Adverse reactions; Pharmacodynamics; Registrational; Therapeutic Use
  • Acronyms ACOUSTICS
  • Sponsors Chugai Pharmaceutical; Roche
  • Most Recent Events

    • 08 Mar 2017 Status changed from active, no longer recruiting to completed.
    • 02 Nov 2016 Planned End Date changed from 1 Apr 2019 to 1 Dec 2016.
    • 02 Nov 2016 Planned primary completion date changed from 1 Apr 2019 to 1 Dec 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top